Sanofi announces the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act of 1976, thereby fulfilling a condition of the French healthcare giant's proposed acquisition of Provention Bio.

On March 24, Sanofi launched a tender offer to acquire all of the outstanding common shares of Provention Bio, at a price of $25 per share. The offer will expire on the evening of April 26, but may be extended.

Closing of the offer is subject to various conditions, including the tender of a certain number of shares which, combined with shares already held by Sanofi and its subsidiaries, represent at least a majority of the outstanding shares.

Copyright (c) 2023 CercleFinance.com. All rights reserved.